$XBI $89.32 | +0.26%
Pipeline Updates
$TCDA +4.9% Tricida Provides Update on Timing of Top-Line Data for the VALOR-CKD Trial Based on Conflict in Ukraine source
$NCNA -57.0%NuCana Announces Update for Phase 3 Biliary Tract Cancer Study source
$SRNE -1.2% Sorrento Announces FDA Authorization to Proceed With Phase 1 Study Of Intranasal STI-9199 (COVISHIELD), a Potent Neutralization Antibody Against Covid-19 Viruses source
$ENDP -5.8% Butt First: Endo Launches First Direct-to-Consumer Campaign for Qwo® (collagenase clostridium histolyticum-aaes) With 200+ Patient Events. source
$IBRX -1.4% Memory Cytokine-Enhanced Natural Killer Cells Show Promising Results in Leukemia Patients; Data Support ImmunityBio’s Scaled m-ceNK Clinical Program. source
$CPRX +3.3% Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio. source
$HARP +16.3% Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217. source
$SIGA +4.7% SIGA Announces Start of TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical Trials. source
$CYTK +4.7% Cytokinetics Announces Cohort 4 of REDWOOD-HCM Is Open to Enrollment. source
$ALXO +4.0% ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer. source
$ADAG -2.9% Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates. source
$CYAD -3.5% Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase
1b Trial. source
Business Updates
$MDWD -21.8% MediWound Ltd. Announces Proposed Public Offering of Ordinary Shares source
Posted by FS/JM
Comments